Olivier Mascle Olivier Mascle

Dr. Olivier Mascle Olivier Mascle


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
CDClaire Dupuis
Claire Dupuis
ABAlexandre Bret
Alexandre Bret
AJAlexandra Janer
Alexandra Janer
OGOlivia Guido
Olivia Guido
RBRadhia Bouzgarrou
Radhia Bouzgarrou
BSBertrand Souweine
Bertrand Souweine

23 November 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LCLaure Calvet
Laure Calvet
FTFrançois Thouy
François Thouy
OMOlivier Mascle Olivier Mascle
Olivier Mascle Olivier Mascle
ASAnne-Françoise Sapin
Anne-Françoise Sapin
KGKévin Grapin
Kévin Grapin
CDClaire Dupuis
Claire Dupuis
COVID 19 is often associated with hypercoagulability and thromboembolic (TE) events. The aim of this study was to assess the characteristics of hypercoagulability and its relationship with new-onset TE events and the composite outcome of need for intubation and/or death in intensive care unit (ICU) patients admitted for COVID. Prospective observational study. Monocentric, intensive care, University Hospital of Clermont Ferrand, France. Patients admitted to intensive care from January 2020 to May 2021 for COVID-19 pneumonia. Standard hemostatic tests and rotational thromboelastometry (ROTEM) were performed on admission and on day 4. Hypercoagulability was defined by at least one of the following criteria: D-dimers > 3000 μg/dL, fibrinogen > 8 g/L, EXTEM CFT below the normal range, EXTEM A5, MCF, Li 60 above the normal range, and EXTEM G-score ((5000 x MCF) / (100-MCF)) ≥ 11 dyne/cm2. Of the 133 patients included, 17 (12.7%) developed new-onset TE events, and 59 (44.3%) required intubation and/or died in the ICU. ROTEM was performed in 133 patients on day 1 and in 67 on day 4. Hypercoagulability was present on day 1 in 115 (86.4%) patients. None of the hypercoagulability indices were associated with subsequent new-onset TE events on days 1 and 4 nor with the need for intubation and/or ICU death. Hyperfibrinogenemia > 8g/dL, higher D-dimers and higher EXTEM Li 60 on day 4 were predictive of need for intubation and/or of ICU death. Our study confirmed that most COVID-19 ICU patients have hypercoagulability on admission and almost all on day 4. Hyperfibrinogenemia or fibrinolysis shutdown on day 4 were associated with unfavorable outcome.

1 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OMOlivier Mascle Olivier Mascle
Olivier Mascle Olivier Mascle
CDClaire Dupuis
Claire Dupuis
MBMarina Brailova
Marina Brailova
BBBenjamin Bonnet
Benjamin Bonnet
AMAudrey Mirand
Audrey Mirand
BSBertrand Souweine
Bertrand Souweine
Introduction: The COVID-19 pandemic has been associated with significant variability in acute kidney injury (AKI) incidence, leading to concerns regarding patient heterogeneity. The study’s primary objective was a cluster analysis, to identify homogeneous subgroups of patients (clusters) using baseline characteristics, including inflammatory biomarkers. The secondary objectives were the comparisons of MAKE-90 and mortality between the different clusters at three months. Methods: This retrospective single-center study was conducted in the Medical Intensive Care Unit of the University Hospital of Clermont-Ferrand, France. Baseline data, clinical and biological characteristics on ICU admission, and outcomes at day 90 were recorded. The primary outcome was the risk of major adverse kidney events at 90 days (MAKE-90). Clusters were determined using hierarchical clustering on principal components approach based on admission characteristics, biomarkers and serum values of immune dysfunction and kidney function. Results: It included consecutive adult patients admitted between March 20, 2020 and February 28, 2021 for severe COVID-19. A total of 149 patients were included in the study. Three clusters were identified of which two were fully described (cluster 3 comprising 2 patients). Cluster 1 comprised 122 patients with fewer organ dysfunctions, moderate immune dysfunction, and was associated with reduced mortality and a lower incidence of MAKE-90. Cluster 2 comprised 25 patients with greater disease severity, immune dysfunction, higher levels of suPAR and L-FABP/U Creat, and greater organ support requirement, incidence of AKI, day-90 mortality and MAKE-90. Conclusions: This study identified two clusters of severe COVID-19 patients with distinct biological characteristics and renal event risks. Such clusters may help facilitate the identification of targeted populations for future clinical trials. Also, it may help to understand the significant variability in AKI incidence observed in COVID-19 patients.

10 October 2026 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OMOlivier Mascle Olivier Mascle
Olivier Mascle Olivier Mascle
CDClaire Dupuis
Claire Dupuis
ALAntoine Lafarge
Antoine Lafarge
MMMaxime Moniot
Maxime Moniot
BEBertrand EVRARD
Bertrand EVRARD
BSbertrand SOUWEINE
bertrand SOUWEINE
Background: The anti-inflammatory effects of COVID-19 and its treatment may promote COVID-19-associated pulmonary aspergillosis (CAPA). This study aimed to investigate the immunological profile associated with CAPA in ICU patients. Methods: We conducted a retrospective study in three French ICUs. Severe COVID-19 patients who underwent immunological profiling within 10 days of ICU admission were included. CAPA patients were matched with non-CAPA patients to assess risk factors. Results: Among 479 non-CAPA patients, 52 were matched with 28 CAPA patients. CAPA patients more frequently required organ support (p < 0.01), but mortality rates were similar. At ICU admission and day 7, CAPA patients had higher serum IL-6, IL-10, and IL-6/mHLA-DR ratios. In univariate conditional logistic regression an mHLA-DR expression > 8000 antibodies/cell at admission was associated with lower CAPA (OR = 0.41 [0.17–0.99], p = 0.04) and CAPA or death (OR = 0.26 [0.08–0.81], p = 0.04). An IL-6/mHLA-DR ratio > 2.8 tended to be associated with CAPA or death (OR = 3.16 [0.98–10.21], p = 0.05). Multivariate analysis did not find an association between immunological data and development of CAPA. Conclusions: We did not find an association between early immunological profiling data and development of CAPA in multivariate analysis. However, mHLA-DR, IL-10 and IL-6/mHLA-DR ratios may be interesting directions for future research with larger cohorts.